APLNR and metabolic dysfunction-associated steatotic liver disease: To further investigate the impact of apelin/APLNR on MASLD, we conducted intraperitoneal injections of apelin and the APLNR antagonist ML221 in the above-mentioned MASLD mouse models (Fig. 3A).